Silexion Therapeutics Corp Warrant (SLXNW)

• Market cap: $76.2K
• 1 day: 0.00%
• 5 days: -8.24%
• 1 month: -37.20%
• 3 months: -33.76%
• 6 months: -17.60%
• Year to date: 64.14%
• 1 year: -54.27%
• 5 years: -54.27%
• 10 years: -54.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Employees: 14

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

117% more capital invested

Capital invested by funds: $91.7K [Q4 2024] → $199K (+$107K) [Q1 2025]

0.27% more ownership

Funds ownership: 23.55% [Q4 2024] → 23.82% (+0.27%) [Q1 2025]

4% less funds holding

Funds holding: 26 [Q4 2024] → 25 (-1) [Q1 2025]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5